TY  - JOUR
T1  - TReatment of human immunodeficiency virus in adults—reply
AU  - Thompson MA, Aberg JA, Volberding PA
Y1  - 2012/10/17
N1  - 10.1001/jama.2012.12889
JO  - JAMA
SP  - 1522
EP  - 1523
VL  - 308
IS  - 15
N2  - 
The panel expects that patients enrolling in ongoing comparisons of the optimal time at which to initiate therapy will be informed of the evidence for early therapy, including risks and benefits, as part of the informed consent process. Although data on early initiation of therapy were derived mostly from large, well-designed observational studies, the panel's recommendation also drew on compelling randomized clinical trial data from the HIV Prevention Trials Network 052 study1 that support early treatment for individual benefit and prevention of transmission.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.12889
UR  - http://dx.doi.org/10.1001/jama.2012.12889
ER  -